A Study on the Association of Hypertension and Hyperparathyroidism in Diabetic Chronic Kidney Disease Patients

Authors

Piyush Saxena¹, Raju Kumar², Arvind Gupta³

¹Assistant Professor, Deptt of Medicine, MLN Medical College, Allahabad, UP INDIA
Email- doc.piyush.saxena@gmail.com

²Resident, Deptt of Medicine, MLN Medical College, Allahabad, UP INDIA

³Professor, Deptt of Medicine, MLN Medical College, Allahabad, UP INDIA

Corresponding Author
Dr Piyush Saxena
Assistant Professor, Deptt of Medicine, MLN Medical College, Allahabad, UP INDIA
Email- doc.piyush.saxena@gmail.com, Mob- 09450110720

Abstract

Introduction: Prevalence of hypertension is high in diabetic CKD patients. Hypertension is one of the important risk factors for cardiovascular diseases in uremic patients. Cardiovascular diseases are the most important etiologies causing mortality and morbidity in these patients. Left ventricular hypertrophy is also found in many CKD patients; its contributing factor other than hypertension is an unsolved issue. Hyperparathyroidism and vitamin D can be the others.

Aims & Objectives: To study the association of Hypertension and Hyperparathyroidism in patients of diabetic CKD. To study the association of Hypertension and vitamin D levels in patients of diabetic CKD. To study the association of Hyperparathyroidism and vitamin D with Left ventricular hypertrophy in patients of diabetic CKD.

Results: Out of 90 cases; The mean serum PTH was 202.37±66.4 pg/mL in prehypertensive group 207±82.7 pg/mL in the patients with stage I Hypertension and 350.5±140.5 pg/mL in the patients with Stage II Hypertension showing significant correlation (P =0.000 ) between Hypertension and iPTH levels. When cases were stratified according to iPTH quartiles (<150, 150-299, 300-449, >450 pg/ml) Systolic Blood Pressure (P =0.0000), and Diastolic Blood Pressure (P =0.000) were found to be significantly correlating with iPTH. Also there is significant relation (P=0.027) between vitamin D levels and development of left ventricular hypertrophy. However no correlation between left ventricular Hypertrophy and i PTH levels was found (P=0.706).

Conclusions: In this study, we could show a significant relationship between hypertension severity and serum i PTH level in diabetic CKD patients. While no association between Hypertension and vitamin D deficiency was found. Left ventricular hypertrophy was significantly related with serum vitamin D levels. However no correlation between left ventricular hypertrophy and i PTH levels was found.

Keywords: CKD, Hypertension, LVH, Hyperparathyroidism, Diabetes, Vitamin D
Introduction
Chronic kidney disease (CKD) is one of the most common and potentially devastating complications of diabetes. Fifty percent of people with diabetes have CKD.\(^1\) It is also important to recognize that people with CKD are among those at highest risk for cardiovascular (CV) morbidity and mortality, and that interventions to lower CV risk remain the most important priority in this population.\(^2\) HTN is the most common cardiovascular disease (CVD) risk factor.\(^3\) Prevention of HTN is possible, and early detection and treatment can reduce the incidence of complications including stroke, CHD, heart failure, and kidney disease.\(^4\) Several factors have been known responsible for hypertension in CKD patients including water and sodium retention due to disturbance in elimination capacity of the kidney, increased activity of renin-angiotension-aldosterone system and sympathetic nervous system, high serum level of vasoconstrictor endothelin-1, and low serum level of vasodilators.\(^5,6\) One of the aetiologies in the development of hypertension in haemodialysis patients is probably high intracellular calcium, due to the secondary hyperparathyroidism. High intracellular calcium increases peripheral artery resistance and probably causes hypertension due to constriction of arteriolar smooth muscles.\(^7\)

Chronically increased plasma intact parathyroid hormone (PTH) concentration and/or intracellular calcium concentration (\([Ca^{2+}]_i\)) may be of relevance in the genesis of high blood pressure. This hypothesis is based on observations that hypertension in uremic patients with secondary hyperparathyroidism is associated with increased PTH and intracellular calcium concentrations.\(^8\) Vitamin D deficiency, is a substantially prevalent condition in patients with type 2 DM.\(^9\) Vitamin D receptors (VDRs) are present on a large variety of cell types, including myocytes, cardiomyocytes, pancreatic beta-cells, vascular Endothelial cells, neurons, immune cells, and osteoblasts.\(^10\) Vitamin D deficiency seems to predispose to hypertension, diabetes and the metabolic syndrome, left ventricular hypertrophy, congestive heart failure, and chronic vascular inflammation.\(^10,11\)

The pathogenesis of LVH in ESRD is multifactorial, and arterial hypertension, hyperparathyroidism, severe anemia, hypoalbuminemia, chronic volume overload,\(^12\) and sympathetic over activity,\(^13\) have been implicated as causative mechanisms responsible for LVH in these patients. An increased prevalence of cardiac structural abnormalities, such as left ventricular hypertrophy (LVH), has been observed in vivo\(^14\) and functional properties of the heart might be affected by the hyperparathyroid condition as well\(^15\).

Materials and Methods
The present study was a single point cross sectional case control study, mainly centered on diabetic chronic kidney disease patients. There detailed history and physical examination (with an accurate measurement of blood pressure –systolic, diastolic) was taken. They were investigated for baseline characteristics including diabetic profile, iPTH, vitamin D levels and 2D echo. All patients of diabetes mellitus and chronic kidney disease admitted in our hospital were taken as cases. Patients having Severe anaemia ,Coronary artery disease Cardiomyopathies Valvular heart disease Previous parathyroidectomy, Connective tissue diseases. were excluded from the study. Age and sex matched volunteers as controls from the hospital were taken to minimize possibility of any bias. They were screened for the absence of diabetes, hypertension and chronic kidney disease. Blood pressure was measured with one calibrated manometer in the supine position. The participants with hypertension were divided based on the stage of hypertension according to the definition of Joint of National Committee for hypertension VII. In all patients, fasting blood sample was taken was analyzed for Complete hemogram (HB,TLC,DLC,ESR ) Serum Urea , Serum Creatinine, Serum calcium, serum phosphate Diabetic profile (Blood sugar fasting, post prandial blood sugar and HbA1c)serum calcium, phosphorous, PTH,
and vitamin D. Other investigations are USG abdomen for kidney size and echotexture. Urine examination, 2D Echo (for Left ventricular mass), X-Ray chest and ECG.

**Statistical Analyses**
Comparisons between the two groups were done using the t test or the chi-square, where appropriate. For comparison between various groups of I PTH and stages of hypertension with various covariables ANNOA was applied. A multiple linear regression model was applied to show serum PTH as independent predictors of systolic and diastolic blood pressure. Data analysis was carried out using the SPSS software (Statistical Package for the Social Sciences, version 17.0, SPSS Inc, Chicago, Ill, USA). P values less than .05 were considered significant.

**Results**
In this single point cross sectional study 140 subjects were studied of which 90 cases were having T2DM and chronic kidney disease and 50 age and sex matched healthy controls who were non hypertensive, non diabetic, non CKD patients admitted for some other illness healthy controls were taken.(Table No.1)
Out of 90 cases; 22 had JNC pre Hypertensive stage, 26 had JNC stage I Hypertension and 30 had JNC stage II Hypertension. The mean serum PTH was 202.37±66.4 pg/mL in prehypertensive group 207±82.7 pg/mL in the patients with stage I Hypertension and 350 ±140.5 pg/mL in the patients with Stage II Hypertension showing significant correlation (P =0.000 ) between Hypertension and iPTH levels while no correlation (p=0.61) was found between hypertension and Vitamin D. (Table no. 2).
When cases were stratified according to iPTH quartiles (<150,150-299,300-449,>450 pg/ml) Systolic Blood Pressure (P =0.0000), and Diastolic Blood Pressure (P =0.000) were found to be significantly correlating with iPTH (Table No. 3). This was also proved by scatter diagram between iPTH and Systolic Blood Pressure (Figure No.1) and between iPTH and Diastolic Blood Pressure. (Figure No.2)
Also there is significant relation (P=0.02) between vitamin D levels and development of left ventricular hypertrophy. However no correlation between left ventricular Hypertirophy and i PTH levels was found (P=0.706).(Table No.4 & 5)
In the multiple linear regression model, serum PTH was a positive and significant predictor of systolic blood pressure (sig. = 0.017) and diastolic blood pressure (sig. = 0.050) when compared to oher co variables (vitamin D ,serum urea).(Table No.6)

**Table no.1** The baseline characteristics of cases and controls

| Characteristics  | Cases       | Controls    | p value |
|------------------|-------------|-------------|---------|
| Age(years)       | 55.44±12.32 | 54.28±12.58 | 0.59    |
| Hb(g/dl)         | 8.62±1.29   | 11.09±1.27  | 0.001   |
| Urea(mg/dl)      | 124.54±65.47| 36.34±10.21 | 0.0001  |
| Creatinine(mg/dl)| 5.03±2.58   | 0.91±0.24   | 0.0001  |
| Calcium(mmol/l)  | 1.08±0.35   | 1.11±0.07   | 0.55    |
| Phosphorus(mg/dl)| 5.02±0.93   | 3.36±0.82   | 0.0001  |
| iPTH(pg/ml)      | 247.63±124.3| 29.55±8.88  | 0.0001  |
| FBS(mg/dl)       | 183.86±50.83| 90.1±8.56   | 0.0001  |
| PPBS(mg/dl)      | 241.33±66.44| 116.9±11.96 | 0.0001  |
| HbA1c(%)         | 7.64±0.85   | 5.81±0.24   | 0.0001  |
| Vitamin D        | 20.66±5.97  | 25.4±7.49   | 0.0001  |
Table no.2 Relation Between JNC VII Stages Of Hypertension with Vitamin D (ng/ml) and iPTH (pg/ml) (mean ± S.D)

| JNC VII Stages of hypertension | iPTH (pg/ml) | Vit D (ng/ml) |
|--------------------------------|--------------|---------------|
| Normotensive(n=12)             | 161.2±63.8   | 18.74±4.32    |
| Pre-hypertensive(n=22)         | 202.37±66.4  | 21.13±6.76    |
| Stage1 HTN (n=26)              | 207±82.7     | 21.39±7.23    |
| Stage 2 HTN (n=30)             | 350.5±140.5  | 21.3±4.98     |
| p-value(ANOVA)                 | 0.000        | 0.610         |

Table no.3 Correlation Between iPTH with systolic blood pressure And Diastolic Blood Pressure (mean ± S.D)

| iPTH (pg/ml) | SYSTOLIC BLOOD PRESSURE(mm of Hg) | DIASTOLIC BLOOD PRESSURE(mm of Hg) |
|--------------|-----------------------------------|-------------------------------------|
| <150(N=23)   | 135.9±25.9                        | 83.3±11.6                           |
| 150-299(N=46)| 145.1±22.02                       | 88±12.01                            |
| 300-449(N=15)| 166.8±15.96                       | 102.1±7.5                           |
| ≥450 (N=6)   | 193.3±11.8                        | 108.7±6.9                           |
| p-value(ANOVA)| 0.000                            | 0.000                               |

Table No.4 .Relation of vitamin D (ng/ml) and LVH (left ventricular hypertrophy) in cases

| Vitamin D level (ng/ml) | Number of cases | LVH present | LVH absent |
|-------------------------|-----------------|-------------|------------|
| < 20 (deficiency)       | 56              | 43(77%)     | 13(23%)    |
| 20-30(insufficiency)    | 23              | 15(65%)     | 8(35%)     |
| >30(sufficiency)        | 11              | 4(36%)      | 7(64%)     |

χ²=7.2 df=2 p= 0.027

Table5. Relation of iPTH Levels(pg/ml) and LVH (left ventricular hypertrophy)

| iPTH levels (pg/ml) | Number of cases | LVH present | LVH absent |
|---------------------|-----------------|-------------|------------|
| <150                | 23              | 12(52%)     | 11(48%)    |
| 150-299             | 46              | 35(76%)     | 11(24%)    |
| 300-449             | 15              | 11(73%)     | 4(27%)     |
| ≥450                | 06              | 06(100%)    | 0(0%)      |

χ²=7.04 df—3 p—0.706

Figure 1: Scatter diagram showing correlation between iPTH And Systolic Blood Pressure
Figure 2: Scatter diagram showing correlation between iPTH and Diastolic Blood Pressure

Table No.6. Multiple Linear Regression With iPTH As Dependent Variable

| Coefficients | Unstandardized Coefficients | Standardized Coefficients | t     | Sig.  |
|--------------|-----------------------------|---------------------------|-------|-------|
| Model        | B                           | Std. Error                | Beta  |       |
| 1 (Constant) | -211.164                    | 78.349                    | -2.695| .008  |
| VIT.D        | -2.913                      | 1.674                     | -.140 | .085  |
| SBP          | 1.775                       | .732                      | .377  | .017  |
| DBP          | 2.874                       | 1.444                     | .310  | .050  |
| S.UREA       | -.054                       | .153                      | -.028 | .725  |

Dependent Variable: iPTH

Discussion
In the study the mean ages of cases were strongly correlating (p=0.007) with the various JNC VII stages of hypertension proving the well known fact for age being one of the most important risk factor for hypertension. These results were in accord to study by Anderson GH et al.\cite{16} in 2009 on 4800 patients and they found increased age to be associated with a significant increase in the prevalence of hypertension and especially of systolic hypertension. In this study it was found that patients with T2DM were having lower Vitamin D levels than those without. 74% of the controls (non diabetics) were having Vitamin D levels more than 20 ng/ml while this percentage was only 48% in the case group i.e. the diabetics. There was significant difference (p= <0.0001) in the mean serum Vitamin D levels between diabetics and the non-diabetics. This suggested that the Vitamin D levels were significantly lower in the case group with more of the patients with hypovitaminosis D. Pietschmann et al.\cite{17} and Isaia et al.\cite{18} showed in their respective studies that an association exists between low circulating concentrations of Vitamin D and the prevalence of diabetes and impaired glucose tolerance.\cite{116, 117} Similar results were found in studies of Pittas et al.\cite{19}, and Gagnon et al.\cite{20} in their respective studies while some studies were not consistent with our finding like Suzuki et al.\cite{21} concluded that mean Vitamin D levels
concentration in T2DM patients was not statistically different from normal population. This may be due to smaller sample, geographical and weather effects.

In the study The JNC VII stages of hypertension were strongly correlating (p=0.000) with I PTH. When the iPTH levels were stratified into quartiles then also the systolic blood pressure (p=0.000) and diastolic blood pressure (p=0.000) were having statistically significant correlation. This finding was consistent with The Tromsø study,22 by Rolf Jorde et al on 10419 subjects, and studies of Helmut Schiffl et al23, and Sedighi et al24. showing association between hypertension and hyperparathyroidism.

In our study no correlation (p=0.61) was found between hypertension and Vitamin D. which was consistent with The Ranch Bernardo Study by Jared P. Reis et al25, on 1070 patients and studies of Andrew St John et al.26, M. B. Snijder et al27. R Chan et al.28 in which parathyroid hormone but not calcitriol remained a significant predictor of mean blood pressure.

In Our study of no relation between vitamin d levels and hypertension (p=0.61) is not consistent with findings of Pfeifer et al.29 and study of Alexandra Jungert et al.30 probable causes can be, firstly we did not measure 1,25-(OH)2-D levels, the most biologically active form of vitamin D, which may have given us more precise information on the biological pathway for its putative effects on blood pressure. Second, our study consisted of moderate sample size of only 90 patients, which decreased the probability of detecting a significant association between serum vitamin D and blood pressure. Third the use of a single measurement of serum 25OHD and PTH May reflects only recent exposure rather than long-term exposure.

In our study a significant correlation between vitamin d levels and left ventricular hypertrophy was found with P=0.027 and df=2. This finding was consistent with Natalya Bodyak et al31 in their study on rats that in the Dahl salt sensitive mice model, and Osman Kuloğlu et al.32 in their study of Serum 25-hydroxyvitamin D levels association with aortic distensibility and left ventricle hypertrophy(p<0.001) in newly diagnosed type 2 diabetes mellitus patients.

In this study no significant correlation was found between I PTH and LVH (p=0.706) which was not accordance with previous studies31-73 by F. N. Saleh et al.33, Al-Hilali et al34, and A. Azak, et al35. This may be due to small sample size of the study and ethnic variations in the study group.

Conclusion

In Diabetics CKD Patients Prevalence of Vitamin D deficiency was significantly higher. Prevalence of Vitamin D deficiency was significantly higher in diabetic patients as compared to non diabetics. The mean serum Vitamin D levels were lower than the non-diabetic non CKD group showing significant association with diabetes. There is significant association between Vitamin D deficiency and Left ventricular hypertrophy. There is significant association between hypertension and Left ventricular hypertrophy. While there is no association between hyperparathyroidism and Left ventricular hypertrophy. There is a inverse correlation between iPTH levels and vitamin D levels. There is significant association between hypertension and age. There is significant association between hyperparathyroidism and systolic blood pressure. There is significant association between hyperparathyroidism and left ventricular hypertrophy. There is no association between Hypertension and vitamin D deficiency.

Limitations

We did not measure 1,25-(OH)2-D levels, the most biologically active form of vitamin D, which may have given us more precise information on the biological pathway for its putative effects on blood pressure. Our study consisted of moderate sample size of 140 patients which decreased the probability of detecting a significant association between serum 25OHD and blood pressure. Patient’s compliance was questionable at certain times.
Bibliography
1. Reenders K, de Nobel E, van den Hoogen HJ, et al. Diabetes and its long term complications in general practice: a survey in a well-defined population. Fam Pract. 1993;10:169-172
2. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
3. Damasceno, A. Azevedo, C. Silva-Matos, et al. Hypertension prevalence, awareness, treatment, and control in mozambique: urban/rural gap during epidemiological transition,” Hypertension, vol. 54, no. 1, pp. 77–83, 2009.
4. Z. H. Israili, R. Hern´andez-Hern´andez, and M. Valasco, “The future of antihypertensive treatment,” American Journal of Therapeutics, vol. 14, no. 2, pp. 121–134, 2007.
5. Horl MP, Horl WH. Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis. 2002;39:227–44.
6. Tycho Vuurmans JL, Boer WH, Bos WJ, et al. Contribution of volume overload and angiotensin II to the increased pulse wave velocity of hemodialysis patients. J Am Soc Nephrol. 2002;13:177–83.
7. Sobotova D, Zharbin A, Svojanovsky J, et al. Hypertension in hemodialyzed uremic patients. Vnitr Lek. 1999;45:641–4.
8. Raine AEG, Bedford L, Simpson AWM, et al. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure Kidney Intern 1993; 43: 700–705
9. Lim S, Kim MJ, Choi SH, et al. Association of vitamin D deficiency with incidence of type 2 diabetes in high-risk Asian subjects. Am J Clin Nutr 2013; 97: 524–530.
10. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–81.
11. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006;92:39–48.
12. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol. 2001;12:1079–1084.
13. Zoccali C, Mallamaci F, Tripepi G, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002;40:41-46.
14. Dominiczak AF, Lyall F, Morton JJ et al. Blood pressure, left ventricular mass and intracellular calcium in primary hyperparathyroidism. Clin Sci 1990;78:127–32.
15. Almqvist EG, Bondeson AG, Bondeson L et al. Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy. Surgery 2002;132:1126–32.
16. Anderson GH. Effect of age on hypertension: analysis of over 4,800 referred hypertensive patients. Saudi J Kidney Dis Transpl. 1999 Jul Sep;10(3):286-97.
17. Pietschmann P, Schernthaner G, Woloszczuk W. Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications. Diabetologia.1988;31: 892–895
18. Isaiac GC, Ardissonne P, Di Stefano M, et al. Bone metabolism in type 2 diabetes mellitus. Acta Diabetol.1999;36: 35–38.
19. Pittas AG, Sun Q, Manson JE, Dawson-Hughes B, et al. Plasma 25 hydroxyvitamin D concentration and risk of incident type 2 diabetes in women. Diabetes Care.2010; 33:2021–2023
20. GagnonC, Lu ZX,Magliano DJ, et al. Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5
years: results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study). Diabetes Care 2011;34;1133–1138.

21. Suzuki et al Hypovitaminosis D in Type 2 Diabetes Mellitus: Association with Microvascular complications and type of treatment Endocrine Journal 2006, 53 (4), 503–510

22. Rolf Jordea, Johan Svardbergb and Johan Sundsfjordc. Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. Journal of Hypertension 2005, Vol 23 No 9.

23. Helmut Schiiff and Susanne M. Lang . Hypertension secondary to PHPT cause or coincidence International Journal of Endocrinology Volume 2011, Article ID 974647, 6 pages.

24. Omid Sedighi,1 Aieh Makhlough, Zahra Kashi, et al. Relationship between serum parathyroid hormone and hypertension in hemodialysis patients Iranian Journal of Kidney Diseases. July 2011; Vol 5 :No 4.

25. Jared P. Reis, Deborah L. Wingard, Elizabeth Barrett Connor. Vitamin D, Parathyroid Hormone Levels, and the Prevalence of Metabolic Syndrome in Community-Dwelling Older Adults. DIABETES CARE, VOLUME 30, NUMBER 6, JUNE 2007;1549–1555

26. Andrew St John, Ian Dick, Kirsten Hoad, et al. Relationship between calcitrophic hormones and blood pressure in elderly subjects. Eur J Endocrinol May 1, 1994 130 446-450

27. M. B. Snijder, P. Lips, J. C. Seidell et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. Journal of Internal Medicine 2007 261; 558–565.

28. R Chan, D Chan, J Woo et al. Serum 25-hydroxyvitamin D and parathyroid hormone levels in relation to blood pressure in a cross-sectional study in older Chinese men. Journal of Human Hypertension (2012) 26, 20–27.

29. Michael Pfeifer, Bettina Begerow, Helmut W. Minne, et al. Effects of a Short-Term Vitamin D3 and Calcium Supplementation on Blood Pressure and Parathyroid Hormone Levels in Elderly Women The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 4.

30. Alexandra Jungert1, Heinz J Roth2 and Monika Neuhäuser-Berthold. Serum 25-hydroxyvitamin D3, parathyroid hormone and blood pressure in an elderly cohort from Germany: a cross-sectional study. Nutrition & Metabolism 2012, 9:20.

31. Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt sensitive animals. Proc Natl Acad Sci USA. 2007;104:16810–16815

32. Osman Kuloğlu, Mustafa Gür, Taner Şeker, et al. Serum 25-hydroxyvitamin D level is associated with aortic distensibility and left ventricle hypertrophy in newly diagnosed type 2 diabetes mellitus. Diabetes & Vascular Disease Research2013; 0(0) 1–4.

33. F. N. Saleh, H. Schirmer, J. Sundsfjord, R. Jorde. Parathyroid hormone and left ventricular hypertrophy. European Heart Journal (2003) 24, 2054–2060

34. Al-Hilali N, Hussain N, Ataia AI, et al. Hypertension and hyperparathyroidism are associated with left ventricular hypertrophy in patients on hemodialysis. Indian J Nephrol. 2009 Oct;19(4):1537.

35. AZAK, E. ABAYLI, M. D. AYLI et al. Cardiac complications of secondary hyperparathyroidism in chronic hemodialysis patients Turk J Med Sci2011; 41 (5): 789-794.